Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Vutrisiran: HELIOS-A Study

Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

Exploratory Biomarker Analyses from HELIOS-B, A Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Baseline Characteristics of Patients with ATTR Amyloidosis Enrolled into the ConTTRibute Registry

Vutrisiran: Cardiac Results from the HELIOS-A Study

Standard response letter on vutrisiran and exploratory cardiac results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with polyneuropathy of hATTR.

Exploratory Analyses from APOLLO-B, A Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study

HELIOS A: Study of Vutrisiran in Patients with hATTR Amyloidosis

Vutrisiran: Arthralgia

Standard response letter on vutrisiran and the adverse event of arthralgia.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.